학술논문

Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL)
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2009, 27 15, 3p. Supplement: S
Subject
Language
English
ISSN
0732183X